Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Medical Device

AK Medical Holdings Receives NMPA Approval for Hip Surgery Navigation System iBot

Fineline Cube Nov 29, 2023

AK Medical Holdings Ltd (HKG: 1789), a Chinese medical technology company, has announced that it...

Company Drug

Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus

Fineline Cube Nov 29, 2023

Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...

Company Deals

Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic

Fineline Cube Nov 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing...

Company Deals

Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production

Fineline Cube Nov 29, 2023

Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has...

Company Drug

Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment

Fineline Cube Nov 28, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...

Company Drug

AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma

Fineline Cube Nov 28, 2023

AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...

Company R&D

AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies

Fineline Cube Nov 28, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with...

Company

Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure

Fineline Cube Nov 28, 2023

German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance...

Company Drug

Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China

Fineline Cube Nov 28, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...

Company Deals

Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round

Fineline Cube Nov 28, 2023

Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200...

Company Drug

Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43

Fineline Cube Nov 28, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...

Company Drug

CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study

Fineline Cube Nov 28, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer

Fineline Cube Nov 28, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of...

Company Deals

Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy

Fineline Cube Nov 28, 2023

Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive...

Company Medical Device

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Fineline Cube Nov 28, 2023

Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...

Company R&D

XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization

Fineline Cube Nov 28, 2023

XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...

Company Drug

Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda

Fineline Cube Nov 28, 2023

Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...

Policy / Regulatory

China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings

Fineline Cube Nov 27, 2023

The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...

Company Deals

DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix

Fineline Cube Nov 27, 2023

South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to...

Company Deals

KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities

Fineline Cube Nov 27, 2023

KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...

Posts pagination

1 … 464 465 466 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.